it was a good article
Dabigatran Approved for Treatment of Venous Thromboembolism — Physician’s First Watch
Dabigatran Approved for Treatment of Venous Thromboembolism
By Larry Husten
The FDA has approved the oral anticoagulant dabigatran (Pradaxa) for the treatment of venous thromboembolism (VTE), the manufacturer announced on Monday.
Dabigatran is now indicated for VTE treatment following therapy with a parenteral anticoagulant for 5 to 10 days. It can also be used to reduce the risk for VTE recurrence in people who've previously been treated.
In 2010, dabigatran was approved for stroke prevention in patients with nonvalvular atrial fibrillation.
Adapted from CardioExchange